Subscribe to RSS - BioScrip

BioScrip

In brief: Hillrom to buy Breathe Technologies; Option Care, BioScrip complete merger

 - 
08/09/2019

CHICAGO – Hillrom has entered into a definitive agreement to buy Breathe Technologies, an Irvine, Calif.-based manufacturer of patented, wearable non-invasive ventilators, for $130 million.

Option Care, BioScrip complete merger

 - 
08/08/2019

BANNOCKBURN, Ill., and DENVER – Option Care Enterprises and BioScrip have completed their merger, forming a newly combined company named Option Care Health.

In brief: BioScrip, Option Care report earnings, NSM makes acquisition

 - 
08/02/2019

DENVER – BioScrip and Option Care both report increased revenues for the second quarter of 2019.

BioScrip, Option Care merger approved

 - 
08/02/2019

DENVER – BioScrip stockholders today approved the merger with Option Care. The merger is expected to close on or about Aug. 6.

BioScrip, Option Care report earnings

Merger expected to be complete in August
 - 
07/31/2019

DENVER – Ahead of their planned merger, BioScrip and Option Care both reported increased revenues for the second quarter of 2019.

BioScrip execs will continue at combined company

 - 
06/13/2019

DENVER – Key members of BioScrip’s leadership team will continue in executive roles with the combined company following the close of its pending merger with Option Care Enterprises.

In brief: KCI sells to 3M, senators introduce accessories bill

 - 
05/03/2019

SAN ANTONIO and NEW YORK – A consortium of funds led by Apax Partners has entered into a definitive agreement to sell Acelity and its KCI subsidiaries worldwide to 3M for about $6.725 billion.

BioScrip reports revenue growth

 - 
05/02/2019

DENVER – BioScrip reported revenues of $179 million for the first quarter of 2019, an increase of 6.2% over the first quarter of 2018. Net loss from continuing operations was $10.3 million vs. $13 million.

Q&A: Option Care's John Rademacher

 - 
04/29/2019

When the ink dries on the planned merger of two of the country’s leading home infusion services providers, it will form an organization that is deeply committed to patient care, says John Rademacher, CEO of the combined company of Option Care and BioScri

Option Care positions itself as ‘partner of choice’

 - 
03/22/2019

DENVER, Colo., and BANNOCKBURN, Ill. – Option Care CEO John Rademacher says its merger with BioScrip will create a “powerful, independent platform” in the growing $100 million infusion market.

Pages